A study by Dr. Steven Nissen, a well-known cardiologist from the Cleveland Clinic, which was published in the New England Journal of Medicine on May 21, concluded that Avandia increases a patient’s risk of a heart attack by 43% and the risk of death from cardiovascular causes by 64%.
The study confirms that 60,000 to 100,000 reported heart attacks from Avandia users may be linked to the drug which has been on the market for 8 years.
Avandia’s manufacturer, GlaxoSmithKlein, PLC, a British company, has sold Avandia to more than 1 million Americans, and 6 million people worldwide, to treat Type II Diabetes which is the most common form of diabetes. Sales in the U.S. reportedly exceeded $2.2 billion last year.
For more information on this subject, please refer to our section on Drugs, Medical Devices, and Implants.